• Patient Site
  • V-Go Customer Care
vgo green
  • Call 1-866-881-1209
  • About V-Go
    • What is V-Go®?
    • Who is it For?
    • How it Works
    • Why V-Go®?
    • Authorized Distributors
  • Clinical Data
    • Optimize Delivery
    • Efficacy
    • Insulin Reduction
    • Patient Adherence
  • Prescribing & Dosing
    • Overview
  • Patient Support
    • Starting Patients
    • Comprehensive Support for You and Your Patients
    • Common Patient Questions
  • Coverage & Savings
    • Overview
  • Pharmacists
    • Overview
    • Reimbursement Card

Better Glycemic Control with Less Insulin

Optimize the Way Insulin is Delivered with V-Go®

V-Go Mimics the Body’s Natural Physiology1

V-Go is an innovative, all-in-one insulin patch that’s proven to deliver effective outcomes by providing patients with a consistent and continuous basal rate as well as on-demand bolus.1-4

 

Error rate was ± 10%.

 

The right amount of insulin at the right time.

V-Go delivers basal-bolus when it’s needed.

MDI=multiple daily injections.
*P<0.0001 compared with baseline.

Efficient Delivery for Better Glycemic Control

Significant and sustained A1c reduction in a broad range of patients with diabetes1

 

 

  • Patients with A1c>7.0% at baseline who were sub-optimally controlled on current diabetes therapy1
  • A1c reductions with V-Go were maintained through 6 months1

 

 

 

Study Design: In a retrospective analysis of an electronic medical records database, patients with uncontrolled diabetes (A1c>7.0%) on previous therapeutic regimens and switched to V-Go were Identified. A total of 153 patients were evaluated. Of these, 86 were on MDI, 45 on basal only, and 22 were insulin naive at baseline.1

Proven to Lower Insulin Requirements

The unique insulin delivery of V-Go significantly lowered basal-bolus requirements2
  • In patients who switched to V-Go from MDI, basal and bolus insulin requirements were reduced by 40% and 48%, respectively2
  • Patients who switched to V-Go from MDI had an average A1c reduction of 1.2% over 6 months
    (P<0.0001)2

 

Study Design: Based on a real-world, retrospective analysis of an electronic medical records database. Patients were adults diagnosed with diabetes mellltus, A1c>7.0%, and previously prescribed basal-bolus Insulin therapy.2

V-Go Demonstrated Reductions in Glucose Variability

Optimized delivery with V-Go improved glycemic profiles and time in range5

 

Insulin Delivered by MDI

 

Insulin Delivered by V-Go

MDI=multiple daily injections; TDD=total daily dose.

 

  • In a 5-week, real-world study using the FreeStyle Libre Pro, patients using V-Go saw a 35% improvement in overall glucose time in range5
  • Overall glucose time below range decreased from 8.7% to 6.6%5
Study Design: A single-center, prospective, pilot study conducted using the FreeStyle Libre Pro in a real-world practice setting was designed to evaluate a percent change in blood glucose time in range (80-140 mg/dL) from baseline in patients switched from MDI to V-Go. Patients were on V-Go for a total of 5 weeks. Seven patients with type 2 diabetes and a stable dose of insulin, with a mean age of 64 years and weight of 226 lb, completed the pilot study.5
FreeStyle Libre Pro Is a registered trademark of Abbott Diabetes Care Inc.
Poster presented at the AACE 27th Annual Scientific and Clinical Congress, Boston, MA, May 2018.
References: 1. Lajara R, Nikkel C. Poster: Evaluating the effect of VGo therapy in suboptimally controlled patients with diabetes: a retrospective cohort analysis in a large specialized diabetes system. Presented at: AACE. May 2015. 2. Lajara R, Nikkel C. Poster: Evaluation of real world clinical and pharmacy budget outcomes when switching to a wearable insulin delivery device for insulin administration in patients with suboptimally controlled diabetes. Presented at: ISPOR. May 2017. 3. Sutton D, Higdon C, Nikkel C, Hilsinger K. Clinical benefits over time associated with use of V-Go Wearable Insulin Delivery Device in adult patients with diabetes: a retrospective analysis. Advances in Therapy 2018 May; 35(5): 631-43. 4. Instructions for Patient Use. P/N 2614-00 Rev. A 05/2019. 5. Parikh S, Dyson J, Nikkel C. Poster: 24 hour wearable basal bolus insulin delivery device improves time in range and treatment satisfaction over multiple daily injections a pilot study. Presented at: AACE. May 2018.
Important Risk Information

If regular adjustments or modifications to the basal rate of insulin are required in a 24-hour period, or if the amount of insulin used at meals requires adjustments of less than 2-Unit increments, use of the V-Go Wearable Insulin Delivery Device may result in hypoglycemia. The following conditions may occur during insulin therapy with V-Go: hypoglycemia (low blood glucose) or hyperglycemia (high blood glucose). Other adverse reactions associated with V-Go use include skin irritation from the adhesive pad or infections at the infusion site. V-Go should be removed before any magnetic resonance imaging (MRI) testing.

  • Product Specs
  • Important Safety Information
  • Contact Us
  • Zealand Pharma
  • Terms of Use & Privacy
  • Cookies
  • Site Map
  • Twitter
  • YouTube
Zealand Pharma Logo Neg (Mar2020) 316x116
White V-Go® logo
© 2021 Zealand Pharma A/S
This website uses cookies to improve your browsing experience. Read MoreAccept
Cookies Policy

Privacy Overview

This website uses cookies to improve your experience while you navigate through the website. Out of these, the cookies that are categorized as necessary are stored on your browser as they are essential for the working of basic functionalities of the website. We also use third-party cookies that help us analyze and understand how you use this website. These cookies will be stored in your browser only with your consent. You also have the option to opt-out of these cookies. But opting out of some of these cookies may affect your browsing experience.
Necessary
Always Enabled

Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.

Non-necessary

Any cookies that may not be particularly necessary for the website to function and is used specifically to collect user personal data via analytics, ads, other embedded contents are termed as non-necessary cookies. It is mandatory to procure user consent prior to running these cookies on your website.